Mercator MedSystems, Inc., an Emeryville, CA-based developer of micro-infusion catheter systems, received $11m in Series D equity financing.
The round was led by Shenzhen Salubris Pharmaceuticals Co., with participation from current investors and other undisclosed new investors.
The company intends to use the funds to further advance the clinical development of its proprietary micro-infusion catheter systems.
Led by Trent Reutiman, chief executive officer, Mercator is a medical device company focused on the clinical and commercial development of proprietary, FDA cleared and CE marked catheter-based micro-infusion technologies, including the Bullfrog® Micro-Infusion Device for delivery in blood vessels and the Blowfish® Transbronchial Micro-Infusion Catheter for delivery in airways.
The company is developing clinical applications in peripheral and coronary artery disease, cancer, hypertension and cardiac regeneration.
Pursuant to the terms of the investment, Salubris secured the exclusive rights to clinically and commercially develop and manufacture the Bullfrog Device in the People’s Republic of China (PRC). Mercator is eligible to receive developmental and sales-based milestone payments, and tiered royalties on sales.